Jim Cramer on Johnson & Johnson: “Their Core Pharma Business is Roaring”

Group 1 - Johnson & Johnson (NYSE: JNJ) has seen a year-to-date increase of approximately 23%, with its stock price reaching around 180 [1] - The company's core pharmaceutical business is performing strongly, particularly in oncology and medical devices, contributing to its positive financial results [1] - JNJ is still facing some challenges related to talc litigation, but these issues are less prominent than before, allowing the company to focus on its strong franchises [1] Group 2 - Johnson & Johnson develops and markets a range of products, including pharmaceuticals, medical devices, and vision care solutions, which encompass therapeutic treatments and surgical technologies [2]